XClose

UCL Queen Square Institute of Neurology

Home
Menu

Publications

Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou N, Carrechio M, Reid E, Heslegrave A, Fenoglio C, Scarpini E, Schott JM, Fox N, Hardy J, Bahtia K, Heales S, Sebire NJ, Zetterberg H, Mills K. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener. 2015 Dec 1;10:64. doi: 10.1186/s13024-015-0059-y

 

Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, Fox NC, Blennow K, Schott JM*, Zetterberg H. (2016). Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology. 86(9):829-835.

 

Cummings DM, Liu W, Portelius E, Bayram S, Yasvoina M, Ho SH, Smits H, Ali SS, Steinberg R, Pegasiou CM, James OT, Matarin M, Richardson JC, Zetterberg H, Blennow K, Hardy JA, Salih DA, Edwards FA. First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression. Brain. 2015 Jul;138(Pt 7):1992-2004.

 

Guerreiro R, Bras J, Toombs J, Heslegrave A, Hardy J, Zetterberg H. Genetic Variants and Related Biomarkers in Sporadic Alzheimer's Disease. Curr Genet Med Rep. 2015;3:19-25.

 

Ling H, Hardy J, Zetterberg H. Neurological consequences of traumatic brain injuries in sports. Mol Cell Neurosci. 2015 May;66(Pt B):114-22.

 

Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, Bhatia K, Morris HR, Giunti P, Warner TT, de Silva R, Lees AJ, Zetterberg H. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015 Jan 14. pii: jnnp-2014-309562. doi: 10.1136/jnnp-2014-309562. [Epub ahead of print]

 

Masca NG, Hensor EM, Cornelius VR, Buffa FM, Marriott HM, Eales JM,… Toombs J et al. RIPOSTE: a framework for improving the design and analysis of laboratory-based research. eLife. 2015;4. Epub 2015/05/08

 

Moore S, Evans LD, Andersson T, Portelius E, Smith J, Dias TB, Saurat N, McGlade A, Kirwan P, Blennow K, Hardy J, Zetterberg H, Livesey FJ. APP metabolism regulates tau proteostasis in human cerebral cortex neurons. Cell Rep. 2015 May 5;11(5):689-96.

 

Paterson RW, Toombs J, Chapman MD, Nicholas JM, Heslegrave AJ, Slattery CF, et al. Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice? Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2015;1(3):380-4

 

Paterson RW, Toombs J, Slattery CF, Nicholas JM, Andreasson U, Magdalinou NK, et al. Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. Journal of neurology. 2015;262(12):2722-30. Epub 2015/09/28

 

Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A, Winblad B, Schott JM, Blennow K, Eriksdotter M, Zetterberg H. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain. 2015 Sep;138(Pt 9):2716-31.

 

Toombs J, Paterson RW, Nicholas JM, Petzold A, Schott JM, Zetterberg H. The impact of Tween 20 on repeatability of amyloid β and tau measurements in cerebrospinal fluid. Clin Chem Lab Med. 2015 Jun 23. pii: /j/cclm.ahead-of-print/cclm-2015-0414/cclm-2015-0414.xml. doi: 10.1515/cclm-2015-0414.

 

Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JR, Zetterberg H, Leavitt BR, Kuhn R, Tabrizi SJ, Macdonald D, Weiss A. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest. 2015 May;125(5):1979-86.

 

 

Ahmed RM, Paterson RW, Warren JD, Zetterberg H, O'Brien JT, Fox NC, Halliday GM, Schott JM. Biomarkers in dementia: clinical utility and new directions. J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1426-34.

 

Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H. CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4. Mol Psychiatry. 2014 Feb;19(2):148-9.

 

Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, Hernandez DG, Nalls MA, Clark LN, Honig LS, Marder K, Van Der Flier WM, Lemstra A, Scheltens P, Rogaeva E, St George-Hyslop P, Londos E, Zetterberg H, Ortega-Cubero S, Pastor P, Ferman TJ, Graff-Radford NR, Ross OA, Barber I, Braae A, Brown K, Morgan K, Maetzler W, Berg D, Troakes C, Al-Sarraj S, Lashley T, Compta Y, Revesz T, Lees A, Cairns N, Halliday GM, Mann D, Pickering-Brown S, Dickson DW, Singleton A, Hardy J. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014 Dec 1;23(23):6139-46.

 

Hardy J, Bogdanovic N, Winblad B, Portelius E, Andreasen N, Cedazo-Minguez A, Zetterberg H. Pathways to Alzheimer's disease. J Intern Med. 2014 Mar;275(3):296-303.

 

Kleinberger G, Yamanishi Y, Suárez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lleó A, Alcolea D, Fortea J, Willem M, Lammich S, Molinuevo JL, Sánchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-Coray T, Hardy J, Colonna M, Haass C. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014 Jul 2;6(243):243ra86.

 

Paterson RW, Toombs J, Slattery CF, Schott JM, Zetterberg H. Biomarker modelling of early molecular changes in Alzheimer's disease. Mol Diagn Ther. 2014 Apr;18(2):213-27.

 

Paterson RW, Bartlett JW, Blennow K, Fox NC; Alzheimer's Disease Neuroimaging Initiative, Shaw LM, Trojanowski JQ, Zetterberg H, Schott JM. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry. 2014 Jul 29;4:e419.

 

Skillbäck T, Farahmand B, Bartlett JW, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A, Winblad B, Rosengren L, Schott JM, Blennow K, Eriksdotter M, Zetterberg H. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014 Nov 18;83(21):1945-53.

 

Toombs J, Paterson RW, Schott JM, Zetterberg H. Amyloid-beta 42 adsorption following serial tube transfer. Alzheimers Res Ther. 2014 Jan 28;6(1):5.

 

Toombs J, Paterson RW, Lunn MP, Nicholas JM, Fox NC, Chapman MD, Schott JM, Zetterberg H. Identification of an important potential confound in CSF AD studies: aliquot volume. Clin Chem Lab Med. 2013 Dec;51(12):2311-7.

 

Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, Schott JM. Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. Biomark Med. 2012 Aug;6(4):391-400.

 

 

Submitted

Heslegrave AJ, Heywood WE, Paterson RW, Svensson J, Johansson P, Öhrfelt A, Blennow K, Hardy J, Schott JM, Mills K, Zetterberg H. Elevated cerebrospinal fluid TREM2 levels in Alzheimer’s disease. Submitted to Mol Neurodegener.